9 results about "FGF1" patented technology

The present invention belongs to the technical field of disease molecular biology, and specifically relates to a biomarker for diagnosis, treatment and prognosis of microvascular invasion of liver cancer and its application. The biomarker includes IQGAP3 protein, which serves as a target for diagnosis, treatment and prognosis of microvascular invasion of liver cancer, and also provides the application of a reagent, test paper or kit for detecting the expression amount of IQGAP3 in the preparation of a reagent for diagnosis, treatment and prognosis of microvascular invasion of liver cancer. The IQGAP3 can be used as a target for intervention of microvascular invasion, and the delivery of IQGAP3 siRNA by nanomaterials can be used as a treatment method for intervention of microvascular invasion of liver cancer, thereby inhibiting the recurrence of intrahepatic and distant metastasis of liver cancer and improving the prognosis of liver cancer patients; and the cytokines FGF1, CTGF and IL8 are highly expressed in the serum of clinical liver cancer patients with positive microvascular invasion, which can be used for diagnosis.

The present invention provides fusion proteins comprising a fibroblast growth factor 1 (FGF1) peptide and a fibroblast growth factor 21 (FGF21) peptide. Pharmaceutical compositions and wound dressings comprising the fusion proteins, polynucleotides encoding the fusion proteins, and methods of using the fusion proteins to treat a condition in a subject are also provided.

The present application relates to the application of Hu sheep FGF1 gene and its coded protein, and belongs to the field of biotechnology. The application of Hu sheep FGF1 gene and its coded protein in regulating the level of oxidative stress, cell apoptosis or cell proliferation of ovary granulosa cells. The present application first systematically identifies the CDS and protein sequence of sheep FGF1 gene, and analyzes its physical and chemical properties, post-translational modification sites, secondary and tertiary structures and systematic evolution relationship, which provides a molecular basis for revealing the role of the gene in oxidative stress and cell fate regulation. In addition, the disclosed sequence information and variation data are helpful for evaluating population genetic diversity, and have important scientific value for the protection, development and evolution research of animal genetic resources.

The present invention discloses the application of cytochrome c oxidase subunit 4 isoform 2 (COX4I2) in the preparation of a predictive biomarker for the prognosis and immunotherapy responsiveness of human colorectal cancer patients. The present invention evaluated the correlation between COX4I2 levels and clinical characteristics and their biological effects in vitro and in vivo, and found that elevated COX4I2 levels were associated with poor prognosis in colorectal cancer patients. Experimental studies also observed that COX4I2 could participate in the epithelial-mesenchymal transition (EMT) of colorectal cancer cells, promote the expression of fibroblast growth factor 1 (FGF1), activate and recruit tumor-associated fibroblasts, and promote tumor angiogenesis. Therefore, COX4I2 can be used as a biomarker for the prognosis of colorectal cancer patients and may also be a new target for therapeutic development.

The present invention provides fusion proteins comprising a fibroblast growth factor 1 (FGF1) polypeptide and a fibroblast growth factor 2 (FGF2) polypeptide. Pharmaceutical compositions and wound dressings comprising the fusion proteins, polynucleotides and constructs encoding the fusion proteins, and methods of using the fusion proteins to treat a condition in a subject are also provided.

To provide a modified fibroblast growth factor chimeric protein enabling maintenance of superior cell growth-promoting activity under a temperature-retaining condition for approximately three days.SOLUTION: The modified fibroblast growth factor chimeric protein according to the present disclosure comprises an FGF chimeric polypeptide (FGFC) in which the sequence at positions 41 to 83 in an amino acid sequence having at least 90% identity to the amino acid sequence of an FGF1 polypeptide of the fibroblast growth factor (FGF) family is replaced by an amino acid sequence having at least 90% identity to the sequence at positions 43 to 85 in the amino acid sequence of an FGF2 polypeptide of the FGF family, and further comprises a GAG-added sequence polypeptide (PG polypeptide) to which a glycosaminoglycan (GAG) sugar chain is bound.SELECTED DRAWING: Figure 1

This invention belongs to the field of aquaculture biotechnology and discloses the application of a grass carp FGF1 recombinant protein in the preparation of products against Aeromonas hydrophila infection. The amino acid sequence of the recombinant protein is shown in SEQ ID NO:2. This invention is the first to discover that this known protein effectively reduces the pathogen load in tissues such as the liver and spleen by repairing the intestinal mucosal physical barrier (significantly increasing the number of intestinal goblet cells, promoting epithelial cell proliferation, and inhibiting apoptosis) and strengthening the immune barrier (upregulating key antibacterial factors such as IL-22, MUC2, Spla2, and HB-EGFa), and significantly increases the 14-day survival rate of grass carp infected with Aeromonas hydrophila from 10% to 56.67%. This invention overcomes the shortcomings of existing technologies that rely solely on in vitro sterilization or are limited to non-infectious factors, providing a green and efficient biological product solution based on host barrier repair for bacterial diseases in grass carp.

The application discloses a fusion FGF1 protein sequence which does not affect the heparin binding capacity and a corresponding DNA sequence, and belongs to the technical field of biology.The nucleotide sequence of the fusion protein FGF1-Pt provided by the application is shown in Seq ID No.10, and the amino acid sequence is shown in Seq ID No.5.The application places Pt at the C-terminal of FGF1, has the best heparin binding capacity without adding a linking peptide, has the highest expression amount of Escherichia coli, and provides materials for the function research of the membrane penetrating peptide of Pt and how Pt affects the spatial structure and activity of FGF1.

The disclosure provides for the culture media particularly suitable to culture primary ostrich PGCs. The culture media contain specific growth factors and compounds that provide support for the growth and proliferation of ostrich PGCs. In certain embodiments, the culture media contain a basal culture medium and β-mercaptoethanol, cholesterol, FGF1, FGF2, BMP4, and IGF1. In some embodiments, the basal culture medium contains knock-out DMEM, B27 Supplement, MEM-MEAA, L-alanyl-L-glutamine dipeptide, cytidine, guanosine, uridine, adenosine, thymidine, sodium pyruvate, ovalbumin, sodium heparin, calcium chloride, ovotransferrin, and an antibiotic. The disclosure also includes methods and kits for producing such media as well as methods of culturing cells.